A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
Abstract
BACKGROUND: We performed a network meta-analysis of the risk of immune-related renal toxicity associated with immune checkpoint inhibitors. METHODS: Eligible studies included randomized trials of patients with immune checkpoint inhibitors; describing events of immune-related renal toxicity. RESULTS: Compared with chemotherapy control, immune checkpoint inhibitors carry a higher risk of all-grade (but not high-grade) immune-related renal toxicity. The risk with both nivolumab/ipilimumab combination was higher than the risk with either ipilimumab or nivolumab alone (odds ratio: 0.47 [95% credible interval: 0.21-0.99] and 0.11 [95% credible interval: 0.03-0.29]); for nivolumab/ipilimumab combination versus ipilimumab or nivolumab monotherapy). CONCLUSION: Our meta-analysis demonstrated that the use of immune checkpoint inhibitors is associated with an increased risk of all-grade immune-related renal toxicity compared with chemotherapy control.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Severe adverse reactions to immune checkpoint inhibitors include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis.
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [99]
The citation lists haven’t been fetched yet
References 43 · Cited by 46
- Authors
- Abdel-Rahman, O., & Fouad, M.
- Affiliations
- Ain Shams University (EG)
- ORCID
- Abdel-Rahman, Omar
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 8
- Issue
- 5
- Pages
- 665-674
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W2346132749
- Cited by
- 46
- References
- 43
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 9 · 2016: 4
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Keywords
- immune-related adverse events, immune checkpoint inhibitors, nivolumab, ipilimumab, cancer immunotherapy, chemotherapy comparison, adverse event risk
- MeSH terms
- Ipilimumab, Nivolumab, Animals, Antibodies, Monoclonal, Carcinoma, Renal Cell, Drug Therapy, Combination, Humans, Kidney, Risk, Randomized Controlled Trials as Topic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
